Findings
========

Introduction
------------

G-protein coupled receptors (GPCRs) represent the largest family of seven transmembrane receptors and downstream signaling constitutes one of the most important signaling pathways to regulate physiological processes. GPCR family members represent a major primary target for drug development \[[@B1],[@B2]\] and their signaling is a predominant focus in the development of novel analgesic therapeutics \[[@B3]\].

Peripheral sensitization is accompanied by an inflammatory milieu, acting on receptors and channels on the peripheral nerve terminals (reviewed in \[[@B4]\]). Most of these sensitizers are known to bind to GPCRs of the G~q/11~ family, the G~i/o~, G~s~ and G~12/13~ family of heterotrimeric G-proteins.

We have recently elucidated the specific significance of the G~q/11~ pathway in modulating properties of nociceptors *in vivo* in the context of physiological pain and pathological states \[[@B5]\]. We found that G~q/11~ is involved in sensitization mechanisms in pathological states and tonically modulates basal nociception and acute pain \[[@B5]\].

There are four members of the G~q/11~-protein family, namely G~q~, G~11~, G~14~ and G~15/16,~ which activate Phospholipase C beta isoforms to regulate intracellular calcium. G~15/16~ overall show very low levels of expression whereas G~14~ has been shown to be expressed at high levels selectively in some tissues (e.g. kidney, lung and spleen; reviewed by \[[@B6]\]), and for the first time Han et al. showed that G~14~ is expressed in a subset of DRG neurons \[[@B7]\] but does not compensate for a loss of G~q/11~\[[@B5]\].

The aim of this study was to investigate the individual role of the G~q~ or G~11~ signaling branch towards acute nociceptive behavior induced by different GPCR ligands specifically activating G~q/11~-coupled GPCRs or GPCRs that are capable to couple different G-protein classes. This is the first study addressing the distinct roles of G~q~ and G~11~ towards nociceptor sensitization.

Methods
=======

All animal use procedures were in accordance with ethical guidelines imposed by the local governing body (Regierungspräsidium Karlsruhe, Germany). All behavioral measurements were done in awake, unrestrained, age-matched mice that were more than 3 months old, by individuals who were blinded to the genotype of the mice being analyzed. Genotypes were identified by genomic tail DNA PCR (as described earlier \[[@B5]\]). Animals were kept on a 12-hour light--dark cycle with constant room temperature and behavioral tests were performed in an appropriate quiet room between 11 am and 4 pm.

We used the following mice, which have been described in detail (except SNS-Gα~q~^-/-^ mice) before (\[[@B5],[@B8]\]): Homozygous mice deficient for Gα~11~ (Gα~11~^-/-^) carrying the floxed allele of the mouse Gα~q~ (Gα~q~^fl/fl^) gene (SNS-Cre^-^;Gα~q~^fl/fl^;Gα~11~^-/-^; referred to as Gα~11~^-/-^ in this manuscript), sensory neuron-specific conditional double deficient mice for Gα~q~ and Gα~11~ (SNS-Cre^+^;Gα~q~^fl/fl^;Gα~11~^-/-^ mice; referred to as SNS-Gα~q/11~^-/-^ in this manuscript), sensory neuron-specific conditional single deficient mice for Gα~q~ (SNS-Cre^+^;Gα~q~^fl/fl^;Gα~11~^+/+^; referred to as SNS-Gα~q~^-/-^ in this manuscript) and mice carrying the floxed allele of Gα~q~ (Gα~q~^fl/fl^; referred to as control in this manuscript).

The following classical algogens and agonists were injected into the plantar surface of the hindpaw in a total volume of 20 μl: 5 μg Glutamate (27 nmol), 0.1 μg Bradykinin (94 nmol), 40 μg UTP (83 nmol), 5 μg CGRP (1.3 nmol), 1 μg mcPAF (1.85 nmol), 1 μg S1P (2.64 nmol), 60 μg ATP (0.1 μmol), 10 μg Serotonin (47 nmol), 50 ng PGE2 (142 nmol), 13U Trypsin, 1U Thrombin. Analysis of latency of paw withdrawal in response to heat was done, as previously described in detail (\[[@B5]\]; Plantar test apparatus, Ugo Basile Inc, Comerio, VA, Italy) and mechanical sensitivity was tested in the same cohort of animals via manual application of von Frey hairs to the plantar surface of the hind paw, as previously described in detail \[[@B5]\]. Two different substances were tested per mouse with 1--2 weeks of recovery period between the applications at different hindpaws. We used 6--8 mice per group, the exact numbers per group are given in Table [1](#T1){ref-type="table"} and the Figure legend.

###### 

**Summary of behavioral results showing main impact of G**~**q**~**-mediating sensitization processes**

     **Ligand**     **Receptor**    **G-protein subclass**     **Thermal hyperalgesia -- paw withdrawal latency**   **Mechanical allodynia -- paw withdrawal response frequency**                                                                                                         
  ---------------- -------------- --------------------------- ---------------------------------------------------- --------------------------------------------------------------- ------------------------- ------------------------- ------------ ------------------ ------------------ -----------------
   **Bradykinin**        B                  G~q/11~                            -51.5 ± 3.3 (n=8)                                          -37.1 ± 2.5 (n=7)                         **-7.4 ± 11.5\*** (n=7)    **-8 ± 2.7\*** (n=7)     54.1 ± 5.5    **27.8 ± 8\***    **14.4 ± 3.6\***   **6.7 ± 5.9\***
      **UTP**           P2Y                 G~q/11~                            -44.2 ± 10.4 (n=8)                                         -23.8 ± 7.2 (n=8)                         **-9.7 ± 7.5\*** (n=7)    **-9.8 ± 5.1\*** (n=8)    32.8 ± 3.2       20 ± 8.9       **4.8 ± 3.5\***    **6.7 ± 6.0\***
    **Trypsin**         PAR                 G~q/11~                             -41 ± 5.7 (n=8)                                            -38.3 ± 5 (n=8)                          **-17.7 ± 3.3\*** (n=8)   **-14.3 ± 8.1\*** (n=6)   -3.3 ± 3.1      4.2 ± 1.8          0.8 ± 0.8               
      **CGRP**          CGRP             G~q/11~, G~s~                         -31,3 ± 6.9 (n=7)                                                                                       -29.2 ± 2.3 (n=8)                                21.1 ± 8.7                         6.7 ± 2.7               
      **ATP**           P2Y              G~q/11~, G~s~                         -48.4 ± 4.6 (n=8)                                          -42.2 ± 6.1 (n=7)                         **-16.7 ± 5.5\*** (n=8)   **-12.3 ± 4.3\*** (n=8)    27.5 ± 2       17.1 ± 6.5      **4.8 ± 3.8\***     **5 ± 2.4\***
      **ET-1**           ET         G~q/11~, G~s~, G~12/13~                     -39.5 ± 4 (n=8)                                           -42.3 ± 6.2 (n=7)                         **-21.7 ± 3.2\*** (n=8)     -25.5 ± 3.9\* (n=7)     26.7 ± 8.5      26.7 ± 5.7      **-0.8 ± 4.4\***    **4.8 ± 5\***
   **PGE**~**2**~        EP          G~q/11~, G~s~, G~i/o~                     -26.8 ± 5.6 (n=8)                                          -22.2 ± 8.8 (n=8)                             -6.6 ± 8 (n=8)            -8 ± 5.7 (n=7)        15.6 ± 5.8      7.5 ± 4.8       **-0.8 ± 2.9\***    **4.8 ± 5\***
   **Serotonin**        5-HT         G~q/11~, G~s~, G~i/o~                     -41.9 ± 3.9 (n=8)                                          -34.4 ± 4.8 (n=8)                            -31.4 ± 3.1 (n=8)       **-24 ± 3.2\*** (n=7)    29.2 ± 5.9   **14.2 ± 5.1\***   **7.5 ± 2.3\***     **2.9 ± 2\***
   **Glutamate**      mGluR1,2          G~q/11~, G~i/o~                        -45.1 ± 11.8 (n=9)                                      **-8.2 ± 6.5 \*** (n=8)                      **-11.2 ± 4.5\*** (n=9)   **-12.5 ± 6.7\*** (n=9)   19.3 ± 9.7      30.4 ± 8.7         3.3 ± 6.3           6 ± 4.7
     **mcPAF**          PAF             G~q/11~, G~i/o~                         -49 ± 1.8 (n=7)                                           -38.7 ± 4.8 (n=8)                             -30.7 ± 5 (n=7)          -26.7 ± 8.3 (n=8)      30.5 ± 5.8      36.7 ± 7.4       **-1 ± 3.1\***    **5.8 ± 5.6\***
    **Thrombin**        PAR        G~q/11~, G~i/o~, G~12/13~                   -27.5 ± 6.2 (n=8)                                                                                        -30.1 ± 5 (n=8)                                  20 ± 3.3                          16.7 ± 8.2              
      **S1P**           S1P        G~q/11~, G~i/o~, G~12/13~                   -51.6 ± 5.7 (n=8)                                           -50.8 ± 5 (n=8)                          **-32.3 ± 4.5\*** (n=8)   **-34.2 ± 7.3\*** (n=8)    23.3 ± 5        20 ± 7.1       **4.2 ± 2.5\***    **0.8 ± 4.1\***

Table displays the mean % change of paw withdrawal latency upon thermal stimulation within 90 min upon GPCR-ligand application to the hindpaw and the delta increase of paw withdrawal frequency upon mechanical stimulation with 0.4 g von Frey filament within 75 min upon GPCR-ligand application. \*p\<0.05 ANOVA, post-hoc Fisher's test and boldface, indicates significant differences towards control mice. n = mice per group for thermal hyperalgesia and mechanical allodynia.

All data are presented as mean ± standard error of the mean (S.E.M.). For multiple comparisons, Analysis of Variance (ANOVA) for random measures was performed followed by post-hoc Bonferroni's test.

Results
=======

The classical deletion of Gα~11~ led to a complete abrogation of Glutamate-induced thermal hyperalgesia (Figure [1](#F1){ref-type="fig"}A, Table [1](#T1){ref-type="table"}) whereas mechanical hyperalgesia was entirely preserved (Table [1](#T1){ref-type="table"}). We found a minor contribution of G~11~ towards Serotonin- induced mechanical hyperalgesia (Figure [1](#F1){ref-type="fig"}D, Table [1](#T1){ref-type="table"}). Interestingly, thermal and mechanical hyperalgesia elicited by PGE~2~, Trypsin, Bradykinin, Endothelin1 (ET1), Sphingosin1 Phosphate (S1P), Platelet-activating factor (PAF), ATP, Thrombin and CGRP were completely preserved in G~11~-deficient mice (Figure [1](#F1){ref-type="fig"}B, [1](#F1){ref-type="fig"}C, [1](#F1){ref-type="fig"}E, [1](#F1){ref-type="fig"}F, Table [1](#T1){ref-type="table"}).

![**Behavioral responses to intraplantar GPCR-ligands in control mice (black square symbols), G**~**11**~^**-/-**^**mice (green triangle symbols), SNS-G**~**q/11**~^**-/-**^**mice (red circular symbols) and SNS-G**~**q**~^**-/-**^**mice (blue cross symbols).** Magnitude and time course of hyperalgesia to plantar heat following unilateral intraplantar hindpaw injection of Glutamate (**A**; n= 9 for control, SNS-G~q~^-/-^ and SNS-G~q/11~^-/-^ mice and n= 8 for G~11~^-/-^ mice) S1P (**B**; n= 8 for all groups) and Thrombin (**C**; n= 8 for both groups) and of mechanical allodynia to mechanical von Frey filament stimulation following unilateral injection of Serotonin (**D**; n= 8 for control, G~11~^-/-^ and SNS-G~q/11~^-/-^ mice and n= 7 for SNS-G~q~^-/-^ mice), mcPAF (**E**; n= 8 for G~11~^-/-^ and SNS-G~q~^-/-^ mice and n= 7 for control and SNS-G~q/11~^-/-^ mice) Endothelin (**F**; n= 8 for control and SNS-G~q/11~^-/-^ mice and n= 7 for G~11~^-/-^ and SNS-G~q~^-/-^ mice). \* *P*\<0.05 as compared to the control group, ^†^ as compared to basal values within a group, ANOVA, post hoc Bonferroni's test. All data points represent mean ± SEM.](1744-8069-9-54-1){#F1}

We analyzed the algogen-induced behavior in G~q/11~ double deficient mice and found a complete loss of thermal hyperalgesia triggered by PGE~2~, Bradykinin, Glutamate, UTP and ATP, as well as mechanical hyperalgesia elicit by PGE~2~, Trypsin, Glutamate, UTP, Serotonin, ET1, S1P, PAF and ATP (Examples in Figure [1](#F1){ref-type="fig"}A, [1](#F1){ref-type="fig"}B, [1](#F1){ref-type="fig"}D-F, Table [1](#T1){ref-type="table"}). There were minor changes with respect to thermal hyperalgesia upon ET1 and S1P application (Example in Figure [1](#F1){ref-type="fig"}B, Table [1](#T1){ref-type="table"}), whereas thermal hyperalgesia towards Thrombin, CGRP and Serotonin and mechanical hyperalgesia towards Thrombin and CGRP was fully preserved in G~q/11~ double deficient mice (Example in Figure [1](#F1){ref-type="fig"}C, Table [1](#T1){ref-type="table"}). Interestingly, the deletion of G~q/11~ in nociceptors had a stronger impact on mechanical allodynia than on thermal hyperalgesia.

Surprisingly, the single deletion of G~q~ caused the same behavioral phenotype as the double deletion of G~q~ and G~11,~ (examples in Figure [1](#F1){ref-type="fig"}, Table [1](#T1){ref-type="table"}) indicating a predominant role for G~q~- over G~11~- proteins in nociceptive neurons.

Discussion
==========

We found that a particular G-protein pathway can contribute differentially to the action of diverse algogens and that a particular algogen can employ different G-protein pathways to elicit thermal hyperalgesia and mechanical allodynia. The G~q/11~ G-protein signaling pathway plays an important role for nociceptor sensitization and the transduction of GPCR signaling towards the development of mechanical allodynia and thermal hyperalgesia with respect to the mediators tested in this manuscript.

To our surprise G~q~ has a major impact over G~11~ mediated nociceptor sensitization. Although G~q~ and G~11~ are nearly ubiquitously expressed in overlapping patterns \[[@B9]\], including the dorsal root ganglia and spinal cord \[[@B7]\], it cannot be ruled out that specific, highly localized differences may exist between the expression pattern and subcellular distribution of G~q~ and G~11~ in central circuits mediating hyperalgesia. Previous studies showing no difference in receptor-coupling with respect to G~q~ or G~11~ are performed *in vitro*\[[@B10]-[@B13]\] and thereby might not reflect the *in vivo* situation. It is more likely that different expression levels as shown for different brain regions \[[@B14]-[@B17]\] or membrane compartmentalization might account for the observed phenotypes. With respect to the DRGs it seems that there is a signaling succession for members of the G~q/11~ family. G~15/16~ are not expressed, G~14~, G~11~ and G~q~ are expressed, while G~14~ has no specific role, G~11~ plays only a minor role for nociceptor sensitization and G~q~ is the most prominent G-proteins of this important signaling family. The classical deletion of G~q~ is known to be lethal \[[@B17]\], indicating essential requirement for this particular G-protein and no possible compensation of other G-proteins from different G-protein classes. Within the G~q/11~ G-protein class, a preferential signaling role of G~q~ over G~11~ signaling has been demonstrated in various systems \[[@B14]-[@B16],[@B18]-[@B20]\] and the G~q~-protein mediated signaling pathway in DRGs seems to have the major role over all other possible G-protein pathways which are involved in signal transduction upon receptor activation after application of ligands. We used the Cre-lox P system for conditional deletion such that the gene deletion only commences prenatally, thereby excluding early developmental deficits in SNS-Gq^-/-^ mice, but we cannot rule out compensatory mechanisms of G~q~ in G~11~^-/-^ mice as it has been suggested earlier \[[@B21]\].

Moreover, we were surprised to see the predominant contribution of the G~q/11~ signaling pathway over G~s~ or G~i/o~ signaling with respect to those substances that are known to activate GPCRs which can bind different classes of G-protein, e.g. ATP, ET1, Glutamate, PAF, PGE~2~, Serotonin, S1P or Thrombin. Whereas the inhibitory G~i/o~ proteins contribute to anti-nociceptive signaling pathway, G~s~ and G~q/11~ protein signaling mediates pro-nociceptive signaling (reviewed in \[[@B3]\]). For example PGE~2~, a crucial mediator for inflammatory pain couples to G~q/11~-, G~i/o~- and G~s~-GPCRs but does not elicit thermal hyperalgesia or mechanical allodynia in mice lacking G~q,~ indicating a major contribution of the G~q~-GPCR signaling pathway. Similarly, ATP or Serotonin, which can bind G~q/11~- and G~s~-GPCRs, do not lead to mechanical allodynia in G~q~-deficient mice indicating a dominant role of G~q~ over the other G-proteins which are known to couple to the same receptors. On the contrary, thermal hyperalgesia and mechanical allodynia induced by CGRP (which can activate G~q/11~- and G~s~- coupled GPCRs) or Thrombin (which can bind G~q/11~- G~i/o~- and G~12/13~-GPCRs) are fully preserved, indicating that compensatory mechanisms via other G-proteins are functional.

Interestingly, with respect to thermal hyperalgesia only ATP-mediated heat hyperalgesia is abrogated in G~q~-deficient mice whereas Serotonin-induced heat hyperalgesia is preserved in these animals. This predominant role of the G~q~-protein in mediating mechanical allodynia over thermal hyperalgesia was also found for Endothelin and to some extend for S1P. It seems that the G~q/11~ signaling pathway contributes significantly to mechanical allodynia elicited via a broad range of inflammatory mediators herein tested and that GPCR agonist-induced heat hyperalgesia is mediated via distinct G-protein GPCRs or other receptors.

Our results constitute a valuable tool to work out *in vivo* conditions of established nociceptive sensitizers. Moreover, this tool can be used for studying the mechanisms of action of new mediators in pain sensitization.
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